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During cell migration, chemoattractant-induced signaling pathways determine the direction of movement by
controlling the spatiotemporal dynamics of cytoskeletal components. In this issue ofDevelopmental Cell, Liu
et al. report that the target of rapamycin complex 2 (TORC2) controls cell polarity and chemotaxis through
regulation of both F-actin and myosin II in migrating neutrophils.Chemotaxis, the ability of cells to direc-
tionally migrate in response to external
cues (chemoattractants), is central to
many normal cell functions that include
the migration of cells in embryonic devel-
opment, immune responses, and wound
healing. Great strides have been made in
our understanding of directed cell migra-
tion during the past decade, revealing
unexpected complexity in the molecular
mechanisms underlying the ability of cells
to perform chemotaxis. The work by Liu
et al. (2010) presented in this issue of
Developmental Cell adds to the mix by
identifying a new pathway through which
the target of rapamycin complex 2
(TORC2) and cAMP control cell polarity
andmotility during neutrophil chemotaxis.
Upon detection of a chemoattractant,
amoeboid cells, such as neutrophils and
Dictyostelium cells, reorganize their cyto-
skeleton and rapidly polarize in the direc-
tion of the chemotattractant source.
Localized polymerization of F-actin at the
front of the cell and assembly of myosin II
in actomyosin filaments at the sides and
rear together provide protrusive and
contractile forces that drive cell motility.
For G protein-coupled receptor (GPCR)-
driven chemotaxis in both neutrophils
and Dictyostelium, ‘‘frontness’’ signaling
pathways include the activation of PI3K
and production of PIP3 at the side of the
cell with the highest chemoattractant
concentration, leading to the local recruit-
ment and activation of PIP3-dependent
guanine exchange factors for the small
GTPase Rac (RacGEFs) that activate
Rac.ActiveRac thendrives localizedpoly-
merization of F-actin, and this ‘‘frontness’’
signaling pathway is amplified through
positive feedback loops involving theactin
cytoskeleton. In neutrophils, the ‘‘back-
ness’’ signaling pathway involves activa-tion of the small GTPase RhoA, which
promotes actomyosin assembly through
activation of the RhoA-dependent kinase
ROCK. ROCK in turn phosphorylates
myosin light chain (MLC) and thereby
activatesmyosin II to promote contraction
of the trailing edge. These ‘‘frontness’’
and ‘‘backness’’ signals appear to be
mediated through distinct heterotrimeric
G proteins: Gi mediates ‘‘frontness’’
signaling to the actin cystoskeleton, while
G12/13 mediates ‘‘backness’’ signaling to
promote myosin II assembly (Wang, 2009
and references therein).
The study by Liu et al. (2010) now
reveals that TORC2 plays a critical role
in neutrophil chemotaxis by regulating
both F-actin and myosin II, probably via
two independent pathways (Figure 1).
Regulation of actin dynamics is a widely
conserved and highly studied function
of TORC2 (Cybulski and Hall, 2009). In
migrating Dictyostelium cells, TORC2
controls both cell motility and the relay
of the chemoattractant signal through
regulation of F-actin polymerization and
activation of adenylyl cyclase, respec-
tively, by modulating the activity of Akt/
PKB and the PKB-related kinase PKBR1
(Lee et al., 2005; Kamimura et al., 2008;
Charest et al., 2010; Cai et al., 2010).
Using an shRNA-mediated knockdown
(KD) of the TORC2-specific component
Rictor, causing loss of TORC2 function,
Liu et al. (2010) show that, in chemotaxing
neutrophils, TORC2 is required for cell
polarity and the spatial regulation of
F-actin, but not its polymerization.
Although chemoattractant-induced F-
actin polymerization is intact in Rictor
KD cells, these cells fail to restrict F-actin
to the side of the cell closest to the che-
moattractant source. Liu et al. (2010)
also found that, as in Dictyostelium cells,Developmental Cell 19, DTORC2 signaling promotes chemoattrac-
tant-induced production of cAMP. In
neutrophils, they show this activity is
specifically mediated through adenylyl
cyclase 9 (AC9). The same group previ-
ously reported that stimulation of human
neutrophils by the chemoattractant and
GPCR ligand fMLP leads to Gi-mediated
activation of AC9, identifying a noncanon-
ical pathway by which GPCRs can stimu-
late cAMP production (Mahadeo et al.,
2007). Although the mechanism by which
TORC2 activates AC9 remains to be
determined, Liu et al. (2010) demonstrate
that it requires the TORC2 substrate PKC
and not Akt/PKB. Interestingly, while
cAMP production is completely inhibited
in AC9 KD cells or upon treatment of
wild-type cells with a PKC inhibitor, the
chemotaxis defects of these cells are not
as severe as those seen in Rictor KD cells.
Unlike Rictor KD cells, cells lacking AC9
or PKC activity show normal localization
of F-actin and, thus, can establish polarity
along the chemoattractant gradient, but
have severe defects in the ability to retract
the cell’s posterior, suggesting that
PKC and AC9 control posterior myosin
II function. Overexpression of AC9, which
results in elevated and unregulated cAMP
accumulation, causes a similar chemo-
taxis defect, suggesting that a cycling of
cAMP levels during chemotaxis is
required for posterior retraction.
Liu et al. (2010) then further showed that
TORC2-mediated and AC9-dependent
cAMP production plays an important
role in modulating the RhoA-ROCK-my-
osin pathway during chemotaxis. They
demonstrate that decreased cAMP pro-
duction because of AC9 KD leads to
increased RhoA activity, resulting in in-
creased ROCK-mediated phosphorylation
of MLC and enhanced ‘‘back’’ activity.ecember 14, 2010 ª2010 Elsevier Inc. 795
Figure 1. TORC2 Controls Neutrophil Polarity and Chemotaxis by Regulating F-Actin
Polarity and Myosin II Assembly
(A) TORC2 is presumably activated at the front of the cells, in a chemoattractant- and Gi-dependent
manner, controlling the polarity of F-actin and locally activating PKC. In turn, PKC promotes the activation
of AC9 and cAMP production.
(B) Through unknown mechanisms, the chemoattractant-stimulated, TORC2/PKC-dependent cAMP
production oscillates and becomes enriched at the posterior of cells, where, most likely through PKA
acting on RhoA and/or MLCK, it regulates the inhibition of myosin II assembly. Fpr, Formyl peptide
receptor. Figure designed and drawn by Jessica Chang.
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lated MLC, a marker for assembled
myosin II, extends to the front of the cells
instead of being restricted to the posterior
and sides. Using an in vivo FRETbiosensor
for cAMP, they also show that cAMP levels
in normal cells are lowest in extending
pseudopodia, while the back of cells dis-
played much higher cAMP levels that
fluctuate dynamically during migration. As
proposed by the authors, these observa-
tions suggest that TORC2-dependent,
transient cAMP accumulations control the
cyclical phosphorylation-dephosphoryla-
tion of myosin II that occurs during neutro-
phil chemotaxis and is required for periodic
back contraction and relaxation. The
mechanism by which cAMP is enriched at
the posterior of migrating neutrophils is
unknown but most likely does not involve
localized activation of AC9 because the
cyclase is uniformly distributed along the796 Developmental Cell 19, December 14, 20plasma membrane of migrating cells and
TORC2 is believed to be activated at the
leading edge in a Gi-dependent manner.
It is also not clear what controls the peri-
odic accumulation of cAMP, but cAMP
production and degradation do neverthe-
less undergo tightly controlled spatiotem-
poral regulation during neutrophil chemo-
taxis and are crucial for efficient
migration. The inhibitory effect of TORC2-
cAMP signaling on the ‘‘backness’’ RhoA-
myosin II pathway most likely occurs
through PKA-mediated inhibition of one
ormore of the components in the pathway.
As discussed by Liu et al. (2010), PKA can
phosphorylate and negatively regulate
RhoA, as well as several RhoGEFs, but
could alternatively exert its inhibitory effect
through phosphorylation-mediated inhibi-
tion of MLC kinase, which also controls
myosin II phosphorylation (Liu et al., 2010
and references therein).10 ª2010 Elsevier Inc.The studies by Liu et al. indicate that
TORC2 plays a key role by integrating
chemotaxis signaling to mediate cell
polarization. As discussed above, pre-
vious evidence suggested that ‘‘front-
ness’’ and ‘‘backness’’ signals are mutu-
ally exclusive and inhibit each other,
underlying the self-polarizing ability of
amoeboid cells (Wang, 2009 and refer-
ences therein). However, the work by Liu
et al. (2010) argues that Gi, a regulator of
‘‘frontness,’’ controls cell polarity through
TORC2 by regulating localized F-actin
polymerization at the front while inhibiting
myosin II assembly through stimulation of
cAMP production at the posterior. Inter-
estingly, Rac1 signaling has a similar
effect in human neutrophil chemotaxis,
in which Rac1 was found to be essential
for RhoA and myosin II activation at the
posterior, while stimulating F-actin poly-
merization at the leading edge (Pestonja-
masp et al., 2006). Thus, a key question
that remains unanswered is how TORC2
mediates F-actin polymerization, which
Liu et al. show is not controlled by
TORC2 activation of Akt.REFERENCES
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